Import Alert 99-39: The Technical Labeling Failure That Triggers Detention Before FDA Examines a Single Unit

Under Import Alert 99-39, the operative question is not whether the product is safe it is whether the label conforms, clause by clause, to the specific labeling provisions of the Federal Food, Drug, and Cosmetic Act.

Import Alert 99-39 is one of the most frequently triggered and least understood compliance mechanisms facing Indian food and dietary supplement exporters. It operates through Detention Without Physical Examination (DWPE) a mechanism that allows FDA to refuse admission based solely on a documentary finding of misbranding, without laboratory testing or physical inspection.

The Statutory Architecture of 99-39

Import Alert 99-39 is titled "Detention Without Physical Examination of Imported Food Products That Appear to Be Misbranded". Its authority derives from Section 801(a)(3) of the FD&C Act, which permits FDA to detain an article of food offered for import when the article appears to be misbranded.

The alert specifically covers violations of the following provisions of Section 403 of the FD&C Act: 403(a)(1), 403(e)(1), 403(e)(2), 403(f), 403(g)(1), 403(g)(2), 403(h)(1), 403(h)(2), 403(i)(1), 403(i)(2), 403(k), 403(q), 403(r)(1)(A)/(B), 403(s)(2)(A), 403(s)(2)(B), 403(s)(2)(C), and 403(y).

For Indian exporters in the food and supplement categories, the most operationally significant among these are:

· Section 403(e)(2) — Net quantity of contents declaration not compliant with 21 CFR 101.7 (position, format, and unit of measure)

· Section 403(i)(2) — Ingredients not listed by their common or usual names

· Section 403(q) — Nutrition information not in the required format (a dietary supplement using "Nutrition Information" rather than "Supplement Facts")

· Section 403(s)(2)(B) — Dietary supplement failing to bear the term "dietary supplement" on the principal display panel

· Section 403(s)(2)(C) — Botanical supplement failing to identify the plant part used

· Section 403(y) — Absence of a US address or phone number for serious adverse event reporting

These are format and declaration violations, not substantive safety failures. A product may be entirely safe and still be detained under 99-39 solely because a mandatory labeling element is absent, mislabeled, or formatted incorrectly.

The Red List Mechanism and the Detention Threshold

The operational consequence of 99-39 is placement on the Red List, which identifies specific manufacturer-product combinations subject to DWPE. Once on the Red List, divisions may detain shipments without physical examination.

The criteria for Red List placement are precise. For violations that do not pose a potentially significant public health hazard, recommendations for DWPE may be made after at least three detentions in a recent six-month period or less, provided those detentions represent at least 25 percent of the total shipments of that product examined in the applicable period. For violations representing a potentially significant health hazard, a single violative entry can suffice.

This threshold matters for Indian exporters because it means the Red List is not triggered by a single unlucky shipment. It is triggered by a pattern and a pattern of labeling errors is often systemic rather than accidental.

Why Indian Supplement Labels Are Structurally Predisposed to 99-39

The technical mismatch between Indian label conventions and FDA requirements is not a matter of carelessness. It is structural. US dietary supplement labeling is governed by DSHEA (1994) and 21 CFR Part 101, which impose requirements that do not map cleanly onto Indian FSSAI conventions.

Four specific failure modes recur:

1. The Supplement Facts panel. Indian products frequently use a nutrition table formatted to Indian conventions. FDA requires a Supplement Facts panel with specified formatting, US measure units, and % Daily Value for declared ingredients. A label built for the Indian market is not a compliant US label with a sticker, it is a rebuild.

2. The statement of identity. FDA requires a statement of identity on the principal display panel for example, "Ashwagandha Root Extract" or "CoQ10 Supplement". A product labeled generically as "Herbal Supplement" does not satisfy the "dietary supplement" requirement under 403(s)(2)(B).

3. Plant part declaration. For botanical supplements, 403(s)(2)(C) requires identification of the plant part used for root, leaf, rhizome, and so on. A label declaring "Ashwagandha Extract" without a separate plant-part declaration is facially non-compliant.

4. The US adverse event contact. Section 403(y) requires a US address or phone number for consumers to report serious adverse events. An Indian address alone does not satisfy this provision.

These are not interpretive ambiguities. They are enumerated statutory requirements, and they are precisely the clauses enumerated in the 99-39 alert text.

The Removal Petition: A Five-Shipment Evidentiary Burden

The consequence of Red List placement extends far beyond a single detained shipment. Removal requires a formal petition to FDA's Division of Import Operations (DIO) demonstrating that the conditions giving rise to the violation have been resolved and that future shipments will be compliant.

In practice, the evidentiary burden is substantial. Many petitions require evidence of at least five consecutive, commercial-size, non-violative shipments tested by a third-party laboratory experienced in FDA testing. The petition must also include a root cause analysis, a Corrective Action Plan (CAP), a Preventive Action Plan (PAP), and updated food safety or HACCP documentation. Small test shipments and incomplete documentation are among the most common reasons petitions are delayed or rejected.

For an Indian SME, this translates into a multi-month evidentiary cycle during which the product remains subject to detention on every entry. The cost is not the label redesign—it is the working capital immobilized during the petition period.

Proffer Compliance: Identifying the Clause Before the Detention Notice

The design premise of Proffer Compliance is that label compliance under 99-39 is a pre-shipment screening problem, not a post-detention remediation problem.

Core capability: an alert tool that flags clause-level risk before FDA does.

Once product information is entered, the Proffer Compliance screening tool evaluates the label against the current provisions of Import Alert 99-39 and related alerts across four dimensions:

1. Clause-level statutory matching. The tool maps the label against each Section 403 sub-clause enumerated in the 99-39 alert text and identifies the specific provision that is missing or non-compliant for example, "403(s)(2)(C) not met: plant part declaration absent." This produces a targeted remediation instruction rather than a generic risk warning.

2. Format validation against 21 CFR 101. For dietary supplement products, the tool verifies whether the Supplement Facts panel conforms to the required format, whether "Nutrition Facts" has been incorrectly used as the heading, and whether the net quantity of contents declaration complies with 21 CFR 101.7 in both position and method.

3. Section 403(y) verification. The tool confirms that a US address or phone number is present and correctly formatted for adverse event reporting.

4. Integration with Proffer's customs and logistics data. Screening results are linked directly to the shipment plan. Where high-risk items are identified, the system issues an alert before the goods leave the port of origin, allowing label correction or supplemental labeling to be completed in India rather than at a US port of entry.

The Compliance Conclusion

Import Alert 99-39 is not an enforcement anomaly. It is a structural feature of the US import regime, one that treats the label as a legal declaration, not a marketing artifact. The alert enumerates the specific statutory clauses that trigger DWPE, and the Red List criteria convert a pattern of labeling errors into a persistent detention burden.

For Indian brands, the operational implication is straightforward. The label must be audited against Section 403 and 21 CFR 101 before the shipment is booked, not after the Notice of FDA Action arrives. A clause identified and corrected at origin costs a label revision. The same clause identified at a US port costs demurrage, storage, and a petition cycle measured in months.

Resolve the label at origin. Do not let it reach the container.

Proffer Compliance supports Indian brands with cross-border compliance screening. To learn how the Compliance tool's labeling screening capability integrates with your export workflow, Write to us at ops@proffer.in to know more.